Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 8, 2025

Rio2 Expands in Latin America With the Acquisition of the Producing Condestable Mine

View original at globenewswire.com
Rio2 Expands in Latin America With the Acquisition of the Producing Condestable Mine Positions Rio2 as a Diversified Latin American Gold Miner with Copper Exposure Concurrent C$140 Million Bought Deal Equity Financing to Support the Acquisition NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATI…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Condestable has 10+ years reserve life and demonstrates year-over-year reserve/resource growth

    80% confidence
  • Pro forma Rio2 will generate approximately US$330M in annual EBITDA

    80% confidence
  • Condestable mine will produce average annual EBITDA of approximately US$110M at consensus prices or US$145M at spot prices for 2026-2030

    80% confidence
  • Post-Fenix Phase 2 (2031+) total production potential is approximately 380,000 oz gold equivalent with gold contributing over 80% of revenue at long-term consensus prices

    80% confidence
  • Near-term production (2027-2028) will be approximately 180,000 oz gold equivalent with copper representing less than 30% of revenue at spot prices

    80% confidence
  • Copper is trading at historic lows relative to gold, making this an opportune time for copper acquisition

    80% confidence
  • Condestable is one of only two operating IOCG mines in Peru

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com